PL376920A1 - Podstawione pochodne 4-alkoksyoksazolu jako agoniści PPAR - Google Patents
Podstawione pochodne 4-alkoksyoksazolu jako agoniści PPARInfo
- Publication number
- PL376920A1 PL376920A1 PL376920A PL37692003A PL376920A1 PL 376920 A1 PL376920 A1 PL 376920A1 PL 376920 A PL376920 A PL 376920A PL 37692003 A PL37692003 A PL 37692003A PL 376920 A1 PL376920 A1 PL 376920A1
- Authority
- PL
- Poland
- Prior art keywords
- alkoxyoxazol
- derivatives
- substituted
- ppar agonists
- ppar
- Prior art date
Links
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02025001 | 2002-11-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL376920A1 true PL376920A1 (pl) | 2006-01-09 |
| PL210871B1 PL210871B1 (pl) | 2012-03-30 |
Family
ID=32309325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL376920A PL210871B1 (pl) | 2002-11-08 | 2003-10-31 | Pochodne oksazolu, sposób ich wytwarzania, środki farmaceutyczne i zastosowanie pochodnych oksazolu |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7109225B2 (pl) |
| EP (1) | EP1572203B1 (pl) |
| JP (1) | JP4551222B2 (pl) |
| KR (1) | KR100699614B1 (pl) |
| CN (1) | CN1711084B (pl) |
| AR (1) | AR041997A1 (pl) |
| AT (1) | ATE377419T1 (pl) |
| AU (1) | AU2003276234B2 (pl) |
| BR (1) | BR0316091A (pl) |
| CA (1) | CA2503117C (pl) |
| DE (1) | DE60317365T2 (pl) |
| ES (1) | ES2295692T3 (pl) |
| MX (1) | MXPA05004743A (pl) |
| PL (1) | PL210871B1 (pl) |
| RU (1) | RU2312106C2 (pl) |
| WO (1) | WO2004041275A1 (pl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| ES2586387T3 (es) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular |
| DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
| US8592377B2 (en) * | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | LIGURE COMBINED POLYPEPTIDES |
| CN102203126A (zh) | 2008-09-22 | 2011-09-28 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| EA022417B1 (ru) * | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Арильные агонисты рецептора gpr120 и их применение |
| US9175047B2 (en) | 2009-01-14 | 2015-11-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| CN102712675A (zh) | 2009-09-22 | 2012-10-03 | 爱勒让治疗公司 | 拟肽大环化合物 |
| ES2711526T3 (es) | 2010-08-13 | 2019-05-06 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| US9487562B2 (en) | 2011-06-17 | 2016-11-08 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of RAB GTPase function |
| ES2861268T3 (es) | 2011-09-20 | 2021-10-06 | Basf Se | Moduladores de bajo peso molecular del receptor de mentol frío TRPM8 y su uso |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| WO2014052647A2 (en) | 2012-09-26 | 2014-04-03 | President And Fellows Of Harvard College | Proline-locked stapled peptides and uses thereof |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| EP3391898A3 (en) | 2013-03-13 | 2019-02-13 | President and Fellows of Harvard College | Stapled and stitched polypeptides and uses thereof |
| JP2016523241A (ja) | 2013-06-14 | 2016-08-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 安定化されたポリペプチドインスリン受容体調節剤 |
| CA2949535C (en) | 2014-05-21 | 2023-09-12 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
| AU2015320545C1 (en) | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2017044633A1 (en) | 2015-09-10 | 2017-03-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of mcl-1 |
| WO2018002215A1 (en) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
| WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW19786A1 (en) * | 1985-10-17 | 1988-05-18 | Hoffmann La Roche | Heterocyclic compounds |
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| GB9712866D0 (en) * | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| JP2002543194A (ja) * | 1999-04-28 | 2002-12-17 | ドクター・レディーズ・ラボラトリーズ・リミテッド | 置換二環系ヘテロ環化合物、その製造方法、並びに抗肥満症及び抗高コレステロール血症剤としてのこれらの使用 |
| JP2001261612A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| CA2418104A1 (en) * | 2000-08-23 | 2002-02-28 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| JP2004509084A (ja) * | 2000-08-23 | 2004-03-25 | イーライ・リリー・アンド・カンパニー | オキサゾリル−アリールオキシ酢酸誘導体およびそのpparアゴニストとしての使用 |
| AU2001284660A1 (en) * | 2000-08-23 | 2002-03-04 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
-
2003
- 2003-10-31 CA CA2503117A patent/CA2503117C/en not_active Expired - Fee Related
- 2003-10-31 MX MXPA05004743A patent/MXPA05004743A/es active IP Right Grant
- 2003-10-31 EP EP03810427A patent/EP1572203B1/en not_active Expired - Lifetime
- 2003-10-31 JP JP2004548844A patent/JP4551222B2/ja not_active Expired - Fee Related
- 2003-10-31 PL PL376920A patent/PL210871B1/pl not_active IP Right Cessation
- 2003-10-31 RU RU2005117964/04A patent/RU2312106C2/ru not_active IP Right Cessation
- 2003-10-31 AT AT03810427T patent/ATE377419T1/de active
- 2003-10-31 AU AU2003276234A patent/AU2003276234B2/en not_active Ceased
- 2003-10-31 WO PCT/EP2003/012189 patent/WO2004041275A1/en not_active Ceased
- 2003-10-31 BR BR0316091-2A patent/BR0316091A/pt not_active IP Right Cessation
- 2003-10-31 ES ES03810427T patent/ES2295692T3/es not_active Expired - Lifetime
- 2003-10-31 DE DE60317365T patent/DE60317365T2/de not_active Expired - Lifetime
- 2003-10-31 KR KR1020057008035A patent/KR100699614B1/ko not_active Expired - Fee Related
- 2003-10-31 CN CN2003801028413A patent/CN1711084B/zh not_active Expired - Fee Related
- 2003-11-04 US US10/700,417 patent/US7109225B2/en not_active Expired - Fee Related
- 2003-11-06 AR ARP030104080A patent/AR041997A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2503117C (en) | 2010-12-21 |
| DE60317365T2 (de) | 2008-08-21 |
| AU2003276234B2 (en) | 2007-04-19 |
| EP1572203B1 (en) | 2007-11-07 |
| RU2312106C2 (ru) | 2007-12-10 |
| CN1711084A (zh) | 2005-12-21 |
| CA2503117A1 (en) | 2004-05-21 |
| KR20050084958A (ko) | 2005-08-29 |
| US7109225B2 (en) | 2006-09-19 |
| AU2003276234A1 (en) | 2004-06-07 |
| WO2004041275A1 (en) | 2004-05-21 |
| ES2295692T3 (es) | 2008-04-16 |
| JP4551222B2 (ja) | 2010-09-22 |
| PL210871B1 (pl) | 2012-03-30 |
| CN1711084B (zh) | 2010-04-28 |
| MXPA05004743A (es) | 2005-08-03 |
| AR041997A1 (es) | 2005-06-08 |
| JP2006508097A (ja) | 2006-03-09 |
| ATE377419T1 (de) | 2007-11-15 |
| DE60317365D1 (de) | 2007-12-20 |
| BR0316091A (pt) | 2005-09-27 |
| EP1572203A1 (en) | 2005-09-14 |
| RU2005117964A (ru) | 2006-03-27 |
| US20040157898A1 (en) | 2004-08-12 |
| KR100699614B1 (ko) | 2007-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL376920A1 (pl) | Podstawione pochodne 4-alkoksyoksazolu jako agoniści PPAR | |
| IL175139A0 (en) | Phenyl derivatives as ppar agonists | |
| IL163928A0 (en) | Pyridinoylpiperidines as 5-htf agonists | |
| AP2005003343A0 (en) | Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors | |
| AP1850A (en) | Spiroindolineplperidine derivatives | |
| IL165810A0 (en) | Novel benzimidazole derivatives | |
| IL166202A0 (en) | Azolidinone-vinyl benzene derivatives | |
| PL373410A1 (pl) | Podstawione indole jako agoniści alfa-1 | |
| IL169905A0 (en) | Novel 2-pyridinecarboxamide derivatives | |
| IL190341A0 (en) | Heterocyclocarboxamide derivatives | |
| SI1551802T1 (sl) | Indol žveplovi derivati | |
| EP1522540A4 (en) | AZAARENE DERIVATIVES | |
| PL376475A1 (pl) | Pochodne N-podstawionej 2-oksodihydropirydyny | |
| IL199668A0 (en) | New benzimidazole derivatives | |
| TWI368482B (en) | New 2-pyridinylethylbenzamide derivatives | |
| PL378342A1 (pl) | Pochodne 2-piperydonu jako agoniści prostaglandyn | |
| IL166426A0 (en) | N-biarylmethyl aminocycloalkanecarboxamide derivatives | |
| IL173521A0 (en) | Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists | |
| SI1551814T1 (sl) | Derivati kiralne oksazol-arilpropionske kisline in njihova uporaba kot ppar-agonisti | |
| AU2003222659A8 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
| EG24415A (en) | Quinoline derivatives | |
| GB0312368D0 (en) | Novel ureido- and amido-pyrazolone derivatives | |
| EP1531854A4 (en) | O-DERIVATED NOCATHIACIN DERIVATIVES | |
| GB0213488D0 (en) | 2-Naphthamide derivatives | |
| AU2003286316A1 (en) | 5-aminophenanthridine derivatives as npy-5 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20121031 |